Key Highlights

  • Shares are trading at $33.53, down 6.55% in Friday's session, pulling back after a roughly 283% surge over the past year.
  • New Phase 1 results for JNJ-1900, the company's lead candidate NBTXR3, showed a promising 79% one-year locoregional tumor control rate in recurrent non-small cell lung cancer.
  • The data also disclosed two Grade 5 (fatal) and eight Grade 3 radiation-related adverse events, raising safety questions that are weighing on sentiment today.
  • The pullback follows a Guggenheim Buy initiation with a $64 price target earlier this week, which had further fueled the stock's recent gains.

Investors Book Profits Following a Historic Run

Nanobiotix (NASDAQ:NBTX) shares pulled back sharply in Friday's session as investors booked profits and digested mixed new clinical data, following a rally that had taken shares up roughly 283% over the past year. Nanobiotix is a Paris-based, late clinical-stage biotechnology company pioneering physics-based nanotherapeutics, with its lead candidate NBTXR3 designed as a sterile aqueous suspension of crystalline hafnium oxide nanoparticles administered by intratumoral injection to enhance the efficacy of radiotherapy against tumors.

New Phase 1 results for JNJ-1900, the company's collaboration with Johnson & Johnson (NYSE:JNJ) through its Janssen division, showed a promising 79% one-year locoregional tumor control rate in recurrent non-small cell lung cancer.

Safety Data Tempers Enthusiasm Despite Strong Efficacy

Alongside the encouraging efficacy signal, the trial disclosed two Grade 5, or fatal, and eight Grade 3 radiation-related adverse events, raising safety questions that appear to be tempering enthusiasm even as the underlying tumor control data remained strong. The disclosure came just days after Guggenheim initiated coverage with a Buy rating and a $64 price target, a call that had further boosted the stock earlier this week.

Pullback Looks Like Digestion Rather Than a Thesis Reversal

The current decline appears to reflect profit-taking and risk reassessment following the recent run-up rather than a Reversal of the broader bullish analyst narrative, with the company's regional Partnership with LianBio continuing to support commercialization plans across Greater China, South Korea, Singapore, and Thailand.